Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 2011. The report discloses a specific corporate transaction regarding a notifiable share interest in Theravance, Inc., rather than providing comprehensive financial results for the period.
Key Financial Metrics
The filing does not provide data on GSK's overall revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to a specific equity purchase:
- Investment Amount: $3,608,988.60
- Shares Purchased: 152,278 shares of Theravance, Inc. Common Stock
- Price Per Share: $23.70
Material Changes
On February 18, 2011, GSK purchased additional shares of Theravance, Inc. to maintain its ownership percentage following net option exercises and equity vesting in the preceding quarter. Following this transaction, GSK's total interest in Theravance comprises 5,902,278 shares of Common Stock and 9,401,499 shares of Class A Common Stock.
Outlook and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies beyond the disclosure of the share purchase. The transaction is noted as disclosable under SEC rules.
Investor Verification Points
- Verify the current total ownership percentage of Theravance, Inc. held by GSK (stated as approximately 19.01% based on 80,503,825 outstanding shares).
- Confirm the terms of the agreement allowing GSK to acquire shares quarterly to maintain its ownership percentage.
- Note that this filing does not contain GSK's consolidated financial performance for the period.